SCHEMBL13434865

SCHEMBL13434865

Cc1csc2c(Nc3ccc(C(N)=O)cc3OC3CCCC3)ncnc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK2 Q9HBH9 6/20 0.44
MKNK1 Q9BUB5 4/20 0.44
EIF4E P06730 1/20 0.41
PDE4D Q08499 3/20 0.41
PDE4A P27815 2/20 0.41
PDE4B Q07343 2/20 0.41
PDE4C Q08493 2/20 0.41
HSP90AB1 P08238 2/20 0.40
TOP2A P11388 2/20 0.40
MAPK13 O15264 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
ALDH1A1 P00352 1/20 0.38
LRRK2 Q5S007 2/20 0.38
BRD4 O60885 1/20 0.38
PLK1 P53350 1/20 0.38
BRDT Q58F21 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13434868 0.89 MKNK2 (0.42) MKNK2MKNK1EIF4EPDE4DPDE4A
SCHEMBL13434855 0.87 MKNK2 (0.48) MKNK2MKNK1MAPK14ALDH1A1LRRK2
SCHEMBL3801706 0.86 MKNK2 (0.51) MKNK2MKNK1EIF4EPDE4DPDE4A
SCHEMBL13434877 0.83 MKNK2 (0.46) MKNK2MKNK1EIF4EPDE4DPDE4A
SCHEMBL13434842 0.83 MKNK2 (0.44) MKNK2MKNK1EIF4EPDE4DPDE4A
SCHEMBL13434866 0.83 MKNK2 (0.56) MKNK2MKNK1EIF4ETOP2ALRRK2
SCHEMBL13434909 0.80 MKNK1 (0.42) MKNK2MKNK1EIF4EPDE4DPDE4A
SCHEMBL18838902 0.80 MKNK2 (0.53) MKNK2MKNK1EIF4E
SCHEMBL3801703 0.79 MEN1 (0.51) MKNK2MKNK1EIF4EPDE4DPDE4A
SCHEMBL13402705 0.79 MKNK2 (0.49) MKNK2MKNK1EIF4EHSP90AB1TOP2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633201-B2 Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-21 US disclosed
US-8633201-B2 Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-21 US disclosed
EP-2004656-B1 THIENOPYRIMIDINES HAVING MNK1 /MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INT (DE) 2013-07-10 EP disclosed
US-20100056548-A1 THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-03-04 US disclosed
US-20100056548-A1 THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-03-04 US disclosed
WO-2007115822-A1 THIENOPYRIMIDINES HAVING MNKL /MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056548-A1 THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS CMPK1, DTYMK, NEK9 MKNK2 8/4885MKNK1 29/4885EIF4E 2334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.